Anixa Biosciences (ANIX) vs Genelux (GNLX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Anixa Biosciences (ANIX) has outperformed Genelux (GNLX) over the past year, losing 28.2% versus a loss of 46.5%. Genelux is the larger company by market cap ($113.1 million vs $101.2 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ANIX | GNLX |
|---|---|---|
| Share price | $2.91 | $2.50 |
| Market cap | $101.16M | $113.11M |
| 1-day change | -1.36% | -0.79% |
| YTD return | -5.45% | -42.20% |
| 1-year return | -28.22% | -46.50% |
| 5-year return | -32.80% | — |
| EPS (TTM) | $-0.32 | $-0.86 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $5.46 | $8.54 |
| 52-week low | $2.32 | $2.29 |
| Distance from 52-week high | -46.70% | -70.71% |
| Average volume | 300.47K | 274.06K |
| Shares outstanding | 34.76M | 45.25M |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ANIX has outperformed GNLX by 18.3 percentage points over the past year.
ANIX vs GNLX FAQ
Which is bigger, Anixa Biosciences or Genelux?
Genelux (GNLX) is larger, with a market capitalization of $113.11M compared with $101.16M for Anixa Biosciences (ANIX).
Which stock has performed better over the past year, ANIX or GNLX?
ANIX returned -28.22% over the past 12 months, compared with -46.50% for GNLX (price return, excluding dividends). Past performance does not predict future results.
Are Anixa Biosciences and Genelux in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.